| Name | PMSF |
| Description | Phenylmethanesulfonyl fluoride (PMSF (Phenylmethylsulfonyl fluoride)) is an enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex. |
| In vitro | Treatment with PMSF (intraperitoneal injection) in mice elicits cannabinoid-like effects, providing analgesia (ED50: 86 mg/kg), hypothermia (ED50: 224 mg/kg), and catalepsy (ED50: 206 mg/kg). When administered to Sprague-Dawley rats, PMSF induces a dose-dependent analgesic effect and significantly potentiates the analgesic effect of β-endorphin in vivo. By inhibiting fatty acid amide hydrolase (FAAH) activity, PMSF suppresses typical cannabinoid or Δ(9)-tetrahydrocannabinol-like effects in ICR mice. Pretreatment with 30 mg/kg PMSF before the injection of [3H]-labeled cannabinoids results in a notable increase in brain cannabinoid levels after 5 minutes compared to [3H]-THC. PMSF pretreatment at 30 mg/kg enhances the cannabinoid-induced effects on the tail-flick response (analgesic effect), locomotion, and spontaneous activity by 5, 8, and 10-fold respectively. Administering PMSF 12 hours before paraoxon (PSP) protects hens from delayed neurotoxicity, whereas administration 4 hours later exacerbates the neurotoxic effects. PMSF pretreatment also prevents organophosphate-induced delayed neuropathy in hens and inhibits neuropathilament degeneration induced by tri-ortho-tolyl phosphate. |
| In vivo | PMSF is a specific inhibitor of phospholipase C involved in the hydrolysis of phosphatidylinositol. In the longitudinal smooth muscle of guinea pig ileum, PMSF (2 mM) almost completely inhibits carbachol-activated synthesis of phosphatidylinositol muscarinic, without affecting synthesis activated by potassium. PMSF transiently inhibits muscle contractions induced by both potassium and carbachol. As an acetylcholinesterase inhibitor, PMSF outperforms BSF (at 8 times the concentration of PMSF), with BSF being sixfold less effective. PMSF rapidly inhibits the activity of trypsin purified from the human pancreas and acetylcholinesterase in human erythrocytes but has a negligible effect on human trypsin. In Trypanosoma brucei, PMSF inhibits the addition of ethanolamine phosphate to the intermediate of glycosylphosphatidylinositol and the acylation of the glycosyl residue in the blood GPI intermediates as well as the addition of ethanolamine phosphate and the acylation of glycosyl in the procyclic form, with no inhibition observed on the latter in mammalian HeLa cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 17.4 mg/mL (99.89 mM), Sonication is recommended.
DMSO : 55 mg/mL (315.75 mM), Sonication is recommended.
|
| Keywords | SerineProtease | Serine Protease | PMSF | Phenylmethylsulfonyl Fluoride | Inhibitor | inhibit | CysteineProtease | Cysteine protease | Cysteine Protease | Cathepsin | Benzylsulfonyl Fluoride |
| Inhibitors Related | Papain | 2-Aminoethanethiol | (S)-(+)-Ibuprofen | Nafamostat mesylate | AEBSF hydrochloride | N-Ethylmaleimide | Aloxistatin | Ceritinib | Aprotinin | 4-Aminobenzamidine dihydrochloride | 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)- | Benzamidine hydrochloride |
| Related Compound Libraries | Highly Selective Inhibitor Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Protease Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library | Anti-Metabolism Disease Compound Library | Human Metabolite Library |
United States
